Two hour exposure to sodium butyrate sensitizes bladder cancer to anticancer drugs

International Journal of Urology

Volumn 15, Issue 5, 2008, Pages 435-441

  Wang, Degui ^a,b   Wang, Zhiping ^a,b   Tian, Binqiang ^a   Li, Xiaoming ^a   Li, Shigang ^b   Tian, Yingxia ^a  

^a Institute of Urology   (Japan)

^b LANZHOU UNIVERSITY   (China)

Author keywords

Bladder cancer; Chemotherapy; Combination; Sodium butyrate

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; ANTINEOPLASTIC AGENT; BUTYRIC ACID; CASPASE 3; CISPLATIN; DOXORUBICIN; FAS ANTIGEN; METHYLNITROSOUREA; MITOMYCIN C; PROTEIN BCL 2;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLADDER CANCER; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG POTENTIATION; FEMALE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; TREATMENT RESPONSE;

ANIMALS; ANTINEOPLASTIC AGENTS; BUTYRATES; CELL LINE, TUMOR; CISPLATIN; DOXORUBICIN; DRUG SYNERGISM; FEMALE; HUMANS; MITOMYCIN; RATS; RATS, WISTAR; TIME FACTORS; URINARY BLADDER NEOPLASMS;

EID: 43049101649     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2008.02025.x     Document Type: Article

References (18)

1. Kaiser M, Zavrski I, Sterz J et al. The effects of the histone deacetylase inhibitor valproic acid on cell cycle, growth suppression and apoptosis in multiple myeloma. Haematologica 2006 91 : 248 51.
2. Verdin E, Dequiedt F, Kasler HG. Class II histone deacetylases: versatile regulators. Trends Genet 2003 19 : 286 93.
3. Heider U, Kaiser M, Sterz J et al. Histone deacetylase inhibitors reduce VEGF production and induce growth suppression and apoptosis in human mantle cell lymphoma. Eur. J. Haematol. 2006 76 : 42 50.
4. Catalano MG, Fortunati N, Pugliese M et al. Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells. J. Clin. Endocrinol. Metab. 2005 90 : 1383 9.
5. Rosato RR, Grant S. Histone deacetylase inhibitors in cancer therapy. Cancer Biol. Ther. 2003 2 : 30 7.
6. Hinnebusch BF, Meng S, Wu JT, Archer SY, Hodin RA. The effects of short-chain fatty acids on human colon cancer cell phenotype are associated with histone hyperacetylation. J. Nutr. 2002 132 : 1012 17.
7. Wang YF, Chen NS, Chung YP, Chang LH, Chiou YH, Chen CY. Sodium butyrate induces apoptosis and cell cycle arrest in primary effusion lymphoma cells independently of oxidative stress and p21 (CIP1/WAF1) induction. Mol. Cell Biochem. 2006 285 : 51 9.
8. Coradini D, Biffi A, Costa A, Pellizzaro C, Pirronello E, Di Fronzo G. Effect of sodium butyrate on human breast cancer cell lines. Cell Prolif. 1997 30 : 149 59.
9. Chen Z, Clark S, Birkeland M et al. Induction and superinduction of growth arrest and DNA damage gene 45 (GADD45) alpha and beta messenger RNAs by histone deacetylase inhibitors trichostatin A (TSA) and butyrate in SW620 human colon carcinoma cells. Cancer Lett. 2002 188 : 127 40.
10. Takai N, Desmond JC, Kumagai T et al. Histone deacetylase inhibitors have a profound antigrowth activity in endometrial cancer cells. Clin. Cancer Res. 2004 10 : 1141 9.
11. Feng WH, Kenney SC. Valproic acid enhances the efficacy of chemotherapy in EBV-positive tumors by increasing lytic viral gene expression. Cancer Res. 2006 66 : 8762 9.
12. Phillips A, Bullock T, Plant N. Sodium valproate induces apoptosis in the rat hepatoma cell line, FaO. Toxicology 2003 192 : 219 27.
13. Catalano MG, Fortunati N, Pugliese M et al. Valproic acid, a histone deacetylase inhibitor, enhances sensitivity to doxorubicin in anaplastic thyroid cancer cells. J. Endocrinol. 2006 191 : 465 72.
14. Qi H, Ratnam M. Synergistic induction of folate receptor beta by all-trans retinoic acid and histone deacetylase inhibitors in acute myelogenous leukemia cells: mechanism and utility in enhancing selective growth inhibition by antifolates. Cancer Res. 2006 66 : 5875 82.
15. Sanchez-Gonzalez B, Yang H, Bueso-Ramos C et al. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Blood 2006 108 : 1174 82.
16. Kuendgen A, Schmid M, Schlenk R et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006 106 : 112 19.
17. Rashid SF, Moore JS, Walker E et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 Dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001 20 : 1860 72.
18. Munshi A, Kurland JF, Nishikawa T et al. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 2005 11 : 4912 22.